光生物调节疗法对头颈癌放疗性口腔黏膜炎疗效的前瞻性双盲自身对照临床试验
该前瞻性双盲自身对照试验纳入53例有两个可比口腔黏膜炎病灶的头颈癌放疗患者,一个病灶接受光生物调节疗法(PBMT),另一个接受假照射对照。结果显示PBMT显著降低OMAS和VAS评分,干预侧完全愈合率52.4%高于对照侧11.9%(P<0.001),且原发癌部位是PBMT后愈合的独立预测因素(aOR 5.78,95%CI 1.28-36.0,P=0.03)。
要点
- PBMT显著降低放疗性口腔黏膜炎的疼痛和病灶严重程度,从第一周起VAS下降,第三周起OMAS下降。
- 干预侧完全愈合率52.4%,对照侧11.9%(P<0.001),PBMT加速恢复且无不良反应。
- 原发癌部位是PBMT后口腔黏膜炎愈合的独立预测因素(aOR 5.78,95%CI 1.28-36.0,P=0.03)。
核心结论
- PBMT与头颈癌放疗患者口腔黏膜炎的疼痛和病灶严重程度显著降低相关,支持其作为支持治疗干预的潜在作用。
研究设计与样本
- 前瞻性双盲自身对照临床试验,筛查163例,最终纳入53例有两个可比口腔黏膜炎病灶的头颈癌放疗或放化疗患者。
- 一个病灶接受PBMT(660 nm,150 mW,每点5 J,每周两次),另一个病灶接受假治疗作为对照,每周用OMAS和VAS评估直至完全愈合或放疗后两周。
主要发现
- PBMT显著降低OMAS和VAS评分,VAS从第一周开始下降,OMAS从第三周开始下降。
- 干预侧完全愈合率52.4%,对照侧11.9%(P<0.001)。
- 多变量回归分析显示原发癌部位是PBMT后放射性口腔黏膜炎愈合的独立预测因素(aOR 5.78,95%CI 1.28-36.0,P=0.03)。
关键数值与推荐
- PBMT参数:660 nm,150 mW,每点5 J,每周两次。
- 疗效评估工具:口腔黏膜炎评估量表(OMAS)和视觉模拟量表(VAS),每周评估。
临床怎么用
- 可考虑将PBMT作为头颈癌放疗性口腔黏膜炎的支持治疗干预,以减轻疼痛和病灶严重程度并促进愈合。
局限性
- 样本量较小(最终分析53例),且为自身对照设计,原发癌部位对疗效的影响需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral mucositis (OM) is a common and painful complication in patients with head and neck cancer (HNC) undergoing radiotherapy or chemoradiotherapy. Photobiomodulation therapy (PBMT) historically referred to as low-level laser therapy (LLLT) has been suggested as a treatment for reducing OM severity and pain. METHODS: In this prospective, double-blind clinical trial, 163 patients were screened, and 53 patients with two comparable OM lesions were ultimately included in the analysis. One lesion received PBMT (660 nm, 150 mW, 5 J per point, twice weekly), and the other received sham treatment as control. Lesion severity and pain were assessed weekly using the Oral Mucositis Assessment Scale (OMAS) and the Visual Analog Scale (VAS) until complete healing or two weeks after radiotherapy. RESULTS: PBMT significantly reduced OMAS and VAS scores compared to control lesions. VAS reduction was observed from the first week, whereas OMAS decreased from week three. Complete healing occurred in 52.4% of intervention lesions versus 11.9% of control lesions (P < 0.001). PBMT accelerated recovery without adverse effects. According to multivariable regression analysis, Primary cancer site was the independent predictive factor of healing of radiation-induced oral mucositis following PBMT (aOR 5.78, 95% CI 1.28-36.0, P = 0.03). CONCLUSIONS: PBMT was associated with a significant reduction in pain and lesion severity in patients with radiation-induced oral mucositis undergoing head and neck radiotherapy. These findings support its potential therapeutic role as a supportive care intervention.
引用
- Ameri A, Lesan M, Vafaei V, et al. Therapeutic effect of Photobiomodulation therapy on radiation-induced oral mucositis in head and neck Cancer: A prospective double-blind, self-controlled clinical trial. Radiother Oncol. 2026. PMID: 41864516. doi:10.1016/j.radonc.2026.111495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。